Jassim, Nazia
Owen, Adrian M.
Smith, Paula
Suckling, John
Lawson, Rebecca P.
Baron-Cohen, Simon
Parsons, Owen
Funding for this research was provided by:
Newnham College, University of Cambridge
NSERC Discovery Grant (RGPIN-2018-05878)
Canada Excellence Research Chairs, Government of Canada (215063)
Canadian Institutes of Health Research (408004)
CIFAR
NIHR Cambridge Biomedical Research Centre
Autistica
Lister Institute of Preventive Medicine
Wellcome Trust Henry Dale Fellowship
Wellcome Trust (214322\Z\18\Z)
Medical Research Council
Innovative Medicines Initiative 2 Joint Undertaking (No 777394)
Autism Centre of Excellence
Simons Foundation Autism Research Initiative
Templeton World Charitable Fund
National Institute for Health Research (NIHR) Applied Research Collaboration East of England
Article History
Received: 30 April 2022
Accepted: 31 August 2022
First Online: 14 September 2022
Competing interests
: NJ, PS, JS, RPL, SBC, and OP report no conflicts of interest. The cognitive tests used in this study are marketed by Cambridge Brain Sciences Inc., of which AMO is the unpaid Chief Scientific Officer. Under the terms of the existing licensing agreement, AMO and his collaborators are free to use the platform at no cost for their scientific studies and such research projects neither contribute to, nor are influenced by, the activities of the company. As such, there is no overlap between the current study and the activities of Cambridge Brain Sciences Inc., nor was there any cost to the authors, funding bodies or participants who were involved in the study.